23.18
Amphastar Pharmaceuticals Inc stock is traded at $23.18, with a volume of 626.12K.
It is down -2.77% in the last 24 hours and up +16.48% over the past month.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$23.84
Open:
$23.47
24h Volume:
626.12K
Relative Volume:
1.32
Market Cap:
$986.03M
Revenue:
$720.53M
Net Income/Loss:
$79.23M
P/E Ratio:
13.92
EPS:
1.6648
Net Cash Flow:
$132.94M
1W Performance:
+5.32%
1M Performance:
+16.48%
6M Performance:
+16.13%
1Y Performance:
-20.59%
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals Inc
|
23.18 | 922.22M | 720.53M | 79.23M | 132.94M | 1.6648 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Aug-12-25 | Upgrade | Needham | Hold → Buy |
| May-12-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-04-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-22-24 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
Legal & General Group Plc Makes New $1.58 Million Investment in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals (AMPH) Rebounds In Focus, Is It Slightly Overvalued? - finance.yahoo.com
Bank of New York Mellon Corp Makes New Investment in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Recommendation of "Reduce" from Analysts - MarketBeat
Amphastar Pharmaceuticals (AMPH) Stock Looks Cheap With Earnings Doing The Heavy Lifting - Yahoo Finance
Rong Zhou Sells 3,187 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock - MarketBeat
Insider sells 3,187 shares at Amphastar (NASDAQ: AMPH) - Stock Titan
A Look at Amphastar Pharmaceuticals Inc (AMPH) After 3.3% Gain -- GF Value $35.96 vs Price $23.74 - GuruFocus
Empowered Funds LLC Invests $3.29 Million in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar (NASDAQ: AMPH) VP plans Rule 144 stock sale led by 10,000-share option exercise - Stock Titan
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference - Stock Titan
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Bank of America Corp DE Acquires 46,149 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals, Inc. $AMPH Stock Holdings Lifted by Algert Global LLC - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Passes Above 50-Day Moving AverageShould You Sell? - MarketBeat
Amphastar Pharmaceuticals Earnings Call Balances Growth And Risk - TipRanks
Denali Advisors LLC Has $7.59 Million Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar (AMPH) Quarterly Results: EPS Exceeds Its Estimate in Latest Trading; Trading Response: The Stock Ends Up 2.30% on the DayEarnings Weakness Phase - Vinanet
Amphastar (NASDAQ: AMPH) insider lines up stock sale after option exercise - Stock Titan
Barclays Issues Positive Forecast for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price - MarketBeat
Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating - marketscreener.com
Is It Too Late to Buy Amphastar Pharmaceuticals Inc (AMPH) After 3.6% Rally? GF Value Says Undervalued - GuruFocus
Lead Independent Director Richard Prins Sold A Bunch Of Shares In Amphastar Pharmaceuticals - simplywall.st
Amphastar Pharmaceuticals (AMPH) Director Richard Prins Sells 7, - GuruFocus
Richard Prins Sells 7,973 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock - MarketBeat
Amphastar director Richard Prins disposes of shares valued at $161,851 By Investing.com - Investing.com South Africa
Amphastar director Richard Prins disposes of shares valued at $161,851 - Investing.com
Director Richard Prins sells 7,973 Amphastar (AMPH) shares at $20.30 - Stock Titan
Amphastar CFO William Peters sells $183,886 in company stock - Investing.com
Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – MUN:29A - TradingView
Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters Sells 8,180 Shares - MarketBeat
Amphastar (AMPH) CFO exercises options and sells 8,180 shares in 10b5-1 trade - Stock Titan
AMPH (AMPH) schedules Rule 144 stock sale tied to RSU vesting - Stock Titan
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Weekly Recap: Amphastar Q2 growth, $100M BAQSIMI and IMS FDA warning - TradingView
Results: Amphastar Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Moomoo
Amphastar Pharmaceuticals (AMPH) Stock Rebound Meets Margin Pressure And Valuation Gap - Sahm
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded by Wall Street Zen to "Strong-Buy" Rating - MarketBeat
Amphastar Pharmaceuticals, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $20.00 by Analysts at Piper Sandler - marketbeat.com
Wells Fargo & Company Increases Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target to $20.00 - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Up After Strong Earnings - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPS - MarketBeat
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Amphastar Pharmaceuticals Q2 Earnings Call Highlights - Yahoo Finance
Amphastar Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026 - Yahoo Finance
Amphastar Pharmaceuticals (NASDAQ: AMPH) Q2 revenue rises 5% with margin gains - Stock Titan
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 - Arizona Daily Star
Pacer Advisors Inc. Buys 83,739 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):